Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXCM DexCom	$80.95 +1.2%	$83.05	$57.52 ▼ $93.25	$31.74B	1.43	3.83 million shs	2.23 million shs
ILMN Illumina	$100.11 +0.0%	$96.81	$68.70 ▼ $156.66	$15.39B	1.37	2.19 million shs	1.53 million shs
ISRG Intuitive Surgical	$480.26 +0.7%	$508.75	$425.00 ▼ $616.00	$172.16B	1.59	2.19 million shs	1.44 million shs
PODD Insulet	$321.27 +1.7%	$298.40	$180.31 ▼ $329.33	$22.62B	1.35	695,485 shs	617,194 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXCM DexCom	+1.24%	+2.65%	-3.78%	-5.30%	+15.56%
ILMN Illumina	+0.02%	+5.87%	+3.25%	+19.72%	-18.13%
ISRG Intuitive Surgical	+0.67%	+2.17%	-6.32%	-14.79%	+1.92%
PODD Insulet	+1.74%	+4.61%	+11.45%	-1.07%	+67.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DXCM DexCom	4.8335 of 5 stars	3.5	4.0	4.7	3.6	2.5	1.9
ILMN Illumina	4.5364 of 5 stars	3.1	3.0	4.2	2.2	1.7	2.5
ISRG Intuitive Surgical	4.6678 of 5 stars	3.3	3.0	4.0	3.6	2.5	1.9
PODD Insulet	4.4078 of 5 stars	2.4	5.0	4.9	3.5	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DXCM DexCom	2.95	Moderate Buy	$99.89	23.40% Upside
ILMN Illumina	2.25	Hold	$124.58	24.44% Upside
ISRG Intuitive Surgical	2.63	Moderate Buy	$595.95	24.09% Upside
PODD Insulet	2.89	Moderate Buy	$330.71	2.94% Upside

Current Analyst Ratings Breakdown

Latest ISRG, PODD, DXCM, and ILMN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	ILMN Illumina	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2025	ILMN Illumina	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$94.00
8/8/2025	PODD Insulet	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$331.00 ➝ $353.00
8/8/2025	PODD Insulet	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$330.00 ➝ $350.00
8/8/2025	PODD Insulet	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$330.00 ➝ $350.00
8/7/2025	PODD Insulet	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
8/7/2025	PODD Insulet	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/4/2025	ILMN Illumina	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$110.00
8/4/2025	ILMN Illumina	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$100.00 ➝ $105.00
8/1/2025	DXCM DexCom	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$106.00
8/1/2025	ILMN Illumina	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$118.00 ➝ $126.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DXCM DexCom	$4.03B	7.87	$2.25 per share	36.02	$6.56 per share	12.34
ILMN Illumina	$4.37B	3.52	$4.69 per share	21.34	$14.69 per share	6.81
ISRG Intuitive Surgical	$8.35B	20.61	$7.99 per share	60.12	$50.08 per share	9.59
PODD Insulet	$2.07B	10.92	$4.44 per share	72.42	$20.78 per share	15.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DXCM DexCom	$576.20M	$1.44	56.22	32.91	1.70	13.29%	30.41%	10.08%	10/23/2025 (Estimated)
ILMN Illumina	-$1.22B	$7.90	12.67	19.40	2.25	29.36%	28.93%	10.74%	11/3/2025 (Estimated)
ISRG Intuitive Surgical	$2.32B	$7.17	66.98	62.94	5.03	28.51%	14.56%	12.93%	10/16/2025 (Estimated)
PODD Insulet	$418.30M	$3.29	97.65	64.64	2.69	10.01%	23.78%	9.30%	N/A

Latest ISRG, PODD, DXCM, and ILMN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	PODD Insulet	$0.92	$1.17	+$0.25	$0.32	$612.31 million	$649.10 million
7/31/2025	Q2 2025	ILMN Illumina	$1.02	$1.19	+$0.17	$1.50	$1.12 billion	$1.06 billion
7/30/2025	Q2 2025	DXCM DexCom	$0.45	$0.48	+$0.03	$0.45	$1.13 billion	$1.16 billion
7/22/2025	Q2 2025	ISRG Intuitive Surgical	$1.93	$2.19	+$0.26	$1.81	$2.35 billion	$2.44 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DXCM DexCom	N/A	N/A	N/A	N/A	N/A
ILMN Illumina	N/A	N/A	N/A	N/A	N/A
ISRG Intuitive Surgical	N/A	N/A	N/A	N/A	N/A
PODD Insulet	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DXCM DexCom	0.48	1.52	1.35
ILMN Illumina	0.66	1.81	1.41
ISRG Intuitive Surgical	N/A	5.17	4.18
PODD Insulet	0.64	2.26	1.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DXCM DexCom	97.75%
ILMN Illumina	89.42%
ISRG Intuitive Surgical	83.64%
PODD Insulet	N/A

Insider Ownership

Company	Insider Ownership
DXCM DexCom	0.32%
ILMN Illumina	2.60%
ISRG Intuitive Surgical	0.70%
PODD Insulet	0.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DXCM DexCom	10,300	392.15 million	390.90 million	Optionable
ILMN Illumina	9,030	153.70 million	149.70 million	Optionable
ISRG Intuitive Surgical	15,638	358.48 million	355.97 million	Optionable
PODD Insulet	3,900	70.39 million	70.12 million	Optionable

ISRG, PODD, DXCM, and ILMN Headlines

Recent News About These Companies

Sei Investments Co. Buys 35,893 Shares of Insulet Corporation (NASDAQ:PODD)

August 16 at 8:20 AM | marketbeat.com

Resona Asset Management Co. Ltd. Sells 924 Shares of Insulet Corporation (NASDAQ:PODD)

August 16 at 4:59 AM | marketbeat.com

Nuveen LLC Invests $74.16 Million in Insulet Corporation (NASDAQ:PODD)

August 15 at 5:00 AM | marketbeat.com

Insulet's (NASDAQ:PODD) Conservative Accounting Might Explain Soft Earnings

August 14 at 4:09 PM | finance.yahoo.com

The Top 5 Analyst Questions From Insulet’s Q2 Earnings Call

August 14 at 11:09 AM | finance.yahoo.com

National Bank of Canada FI Decreases Stock Position in Insulet Corporation (NASDAQ:PODD)

August 14 at 4:24 AM | marketbeat.com

Citigroup Inc. Raises Stake in Insulet Corporation (NASDAQ:PODD)

August 14 at 4:24 AM | marketbeat.com

Insulet's Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold

August 13 at 11:55 PM | seekingalpha.com

PODD Q2 Deep Dive: Omnipod 5 Adoption and International Expansion Drive Results

August 13 at 8:36 AM | finance.yahoo.com

Mizuho Securities USA LLC Sells 1,032 Shares of Insulet Corporation (NASDAQ:PODD)

August 13 at 4:49 AM | marketbeat.com

Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise

August 12, 2025 | zacks.com

Insulet Corp (PODD)'s Winning Formula: Financial Metrics and Competitive Strengths

August 11, 2025 | gurufocus.com

Why Insulet (PODD) is a Top Growth Stock for the Long-Term

August 11, 2025 | zacks.com

Insulet Corporation (NASDAQ:PODD) Stock Position Reduced by Forsta AP Fonden

August 11, 2025 | marketbeat.com

Insulet Corporation (NASDAQ:PODD) Stock Position Lifted by Mitsubishi UFJ Asset Management Co. Ltd.

August 11, 2025 | marketbeat.com

Charles Schwab Investment Management Inc. Boosts Stake in Insulet Corporation (NASDAQ:PODD)

August 11, 2025 | marketbeat.com

ASR Vermogensbeheer N.V. Takes Position in Insulet Corporation (NASDAQ:PODD)

August 11, 2025 | marketbeat.com

Vanguard Group Inc. Purchases 178,976 Shares of Insulet Corporation (NASDAQ:PODD)

August 11, 2025 | marketbeat.com

Wall Street Zen Upgrades Insulet (NASDAQ:PODD) to "Buy"

August 11, 2025 | americanbankingnews.com

Insulet (NASDAQ:PODD) Given New $350.00 Price Target at Wells Fargo & Company

August 11, 2025 | americanbankingnews.com

Leerink Partnrs Brokers Raise Earnings Estimates for Insulet

August 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ISRG, PODD, DXCM, and ILMN Company Descriptions

DexCom NASDAQ:DXCM

$80.95 +0.99 (+1.24%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$80.53 -0.42 (-0.53%)

As of 08/15/2025 07:51 PM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Illumina NASDAQ:ILMN

$100.11 +0.02 (+0.02%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$100.63 +0.52 (+0.52%)

As of 08/15/2025 07:54 PM Eastern

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Intuitive Surgical NASDAQ:ISRG

$480.26 +3.18 (+0.67%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$479.80 -0.46 (-0.10%)

As of 08/15/2025 07:59 PM Eastern

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

Insulet NASDAQ:PODD

$321.27 +5.49 (+1.74%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$322.07 +0.80 (+0.25%)

As of 08/15/2025 04:20 PM Eastern

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time